Innovo Therapeutics develops protein degrader drugs that utilize targeted protein degradation technology to enhance the efficacy of anti-cancer treatments. Their approach aims to improve tumor response rates by enabling precise degradation of specific proteins involved in cancer progression.
Funding
$29.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current anti-cancer treatments often face limitations in efficacy due to the inability to effectively target and eliminate specific proteins that drive cancer progression. Traditional drug development approaches may struggle to address the complex mechanisms of tumor growth and resistance.
Solution
Innovo Therapeutics is developing a new class of anti-cancer drugs based on targeted protein degradation. This technology enables the precise removal of disease-causing proteins, offering a more effective approach to disrupting cancer pathways. By selectively degrading specific proteins involved in tumor growth and survival, Innovo Therapeutics aims to enhance the efficacy of anti-cancer treatments and improve patient outcomes. Their approach focuses on overcoming the limitations of traditional therapies by directly addressing the root causes of cancer progression at the molecular level.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective treatment options.
Features
- Utilizes targeted protein degradation technology for precise protein elimination.
- Focuses on degrading specific proteins involved in cancer progression.
- Aims to enhance the efficacy of anti-cancer treatments.
- Designed to improve tumor response rates.